Genmab Receivables 2010-2024 | GNMSF

Genmab receivables for the quarter ending September 30, 2024 were $0.930B, a 17.28% increase year-over-year.

  • Genmab receivables for 2023 were $0.718B, a 16.19% decline from 2022.
  • Genmab receivables for 2022 were $0.857B, a 58.54% increase from 2021.
  • Genmab receivables for 2021 were $0.541B, a 30.12% increase from 2020.

Genmab Receivables 2010-2024 | GNMSF

  • Genmab receivables for 2023 were $0.718B, a 16.19% decline from 2022.
  • Genmab receivables for 2022 were $0.857B, a 58.54% increase from 2021.
  • Genmab receivables for 2021 were $0.541B, a 30.12% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141B
Bristol Myers Squibb (BMY)$113.2B
Gilead Sciences (GILD)$112B
Vertex Pharmaceuticals (VRTX)$105.5B
CSL (CSLLY)$84.4B
Regeneron Pharmaceuticals (REGN)$76.6B
GSK (GSK)$68.6B
Argenex SE (ARGX)$39.6B
Alnylam Pharmaceuticals (ALNY)$30.7B
BioNTech SE (BNTX)$29.5B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.7B
BeiGene (ONC)$17.3B
Moderna (MRNA)$16.3B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.8B
Sarepta Therapeutics (SRPT)$11.9B
Insmed (INSM)$11.7B
Bio-Techne Corp (TECH)$11.6B
Exact Sciences (EXAS)$10.5B
Exelixis (EXEL)$10.3B
QIAGEN (QGEN)$10.2B
Vaxcyte (PCVX)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Intra-Cellular Therapies (ITCI)$10.1B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$8.7B
Ascendis Pharma (ASND)$7.8B
Roivant Sciences (ROIV)$7.7B